Business Wire

B2Broker Announces Ultra-Competitive New Margin and Crypto Spot Liquidity Pricing Structure

26.10.2021 10:00:00 EEST | Business Wire | Press release

Share

B2Broker, a leading technology and liquidity provider in the Forex and Crypto industry, has announced the introduction of a series of outstanding new conditions for its Margin and Crypto Spot liquidity offerings. With today’s announcement comes a new pricing structure that delivers an ultra competitive proposition which is unmatchable in the industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026005100/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

B2Broker delivers the deepest liquidity pools for FX, Metals, Crypto and CFDs. Our liquidity solutions are used by different types of financial institutions. (Graphic: Business Wire)

B2Broker launched its initial Crypto CFD offering back in 2017, starting with 30 Crypto CFD pairs. The company was the first in this space to implement a Prime Broker business model approach in the Crypto CFD offering. Today, it offers a total of 115 Crypto pairs making it the industry’s leading Crypto CFD provider as well as a tier 1 liquidity provider in the Spot FX, Metals, Equity Indices, Commodities, Single Stocks, and ETFs space all from a single margin account.

To date, B2Broker is used by more than 50% of FX Retail Brokers/Props Houses/Funds, etc, who offer Crypto CFDs and require a main liquidity provider or secondary source of liquidity.

Margin Liquidity

As the popularity of margin trading continues to reach new heights, the new trading conditions from B2Broker will enable its clients to benefit from a whole range of new features and advantages. These include:

New Crypto CFDs

We have added a further 15 new crypto CFDs to our liquidity pool that have proved highly popular recently:

XRP, Cardano, Dogecoin, Solana, Polkadot, Chainlink, Polygon, Uniswap, HIBA INU, Algorand, Avalanche, Terra, Filecoin, Vechain and Maker.
Note: all trade against the USD.

New Margin Requirements

New margin requirements on major crypto CFDs have been decreased from 20% to 10%. This will allow greater opportunities for traders around the world to leverage our unbeatable conditions.

The list of symbols that we have applied changes to include:

BTC/USD, BCH/USD, ETH/USD, LTC/USD, XRP/USD
BTC/EUR, BCH/EUR, ETH/EUR, LTC/EUR, XRP/EUR
BTC/GBP, BCH/GBP, ETH/GBP, LTC/GBP

New Pricing Policy

New commercial offers have been introduced to serve all types of business models. Whether you need a white label solution, a FIX API/gateway connection or an enterprise solution, B2Broker offers a bespoke proposition that serves your business according to your requirements.

Our new Enterprise offering includes PrimeXM or OneZero HUB along with a liquidity solution that gives brokers greater flexibility in terms of managing their liquidity price streams and risk management solutions. The main idea behind this package is to offer broker dealers a solution where they will be able to use our liquidity along with leading HUBs/XCOREs in a more efficient and cost-effective way. For example, if you go directly to PrimeXM or OneZero and buy a Hub with them and then approach B2Broker to buy liquidity, it will prove to be more expensive than simply buying a single Enterprise pack from B2Broker.

The Enterprise liquidity solution is ideal for Brokers who have their own Trading Server such as MT5, MT4, C-Trader etc, and want to be able to manage their price streams, markups, swaps, risk management and more.

New Liquidity Pool Locations

Our liquidity pools are now based in main locations around the world such as LD4, NY4, TY3, SG1 and Mainland China (Beijing). You can choose the best suitable location for your API/Gateway connection.

For our WL clients based in LD4, we have created a global network of access servers which provide the lowest latency connection from any point in the world.

Liquidity Distribution

We offer liquidity distribution across the following platforms to cater for the broad-based demands of our clients PrimeXM, OneZero, FixAPI, MT5, MT4 for FX/CFD, Crypto CFDs etc and B2Trader, Rest API and WEBSocket for Crypto Spot liquidity.

Crypto Spot Liquidity

On the Crypto Spot liquidity side of things, we have introduced a range of outstanding new developments which are applicable to B2BX:

A. Revised ultra-competitive commission ladder which goes down to 0.04%.

B. In total we have enhanced the depth of order book to 100 levels per each side (Buy and Sell) to satisfy the requirements of major players. The compressed order book contains over 120 BTC with an average spread of just $7 USD and market impact of around $140 USD.

C. Increased our trading pairs to consist of additional stable coins and all the top tokens.

B2Broker CEO, Arthur Azizov commented, “We constantly seek to improve our offers and are positioned to offer an unbeatable pricing structure for our services, as well as other favourable conditions which will ultimately benefit our clients. Our liquidity services can be accessed quickly and easily with the most advantageous prices available within the industry and the highest level of technical support”.

B2Broker’s liquidity solutions are used by various types of financial institutions who benefit from our expertise and technology, and our ability to deliver customised liquidity solutions tailored to our clients exact needs. B2Broker offers liquidity on Spot FX, Metals, Commodities, Single Stocks with over 400 instruments, working as a PoP, rather than a market maker. We are therefore on the broker’s side at all times, enabling the best possible liquidity provision in keeping with our clients’ interests.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rosemary Barnes
Head of PR
pr@b2broker.net
www.b2broker.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye